 |
Italian Scientists and Scholars of North America Foundation
|
|
Home > USA > Meet Italy at Bio 2007
CREABILIS THERAPEUTICS SpA
Via Ribes,5 - 10010 Coleretto Giacosa (TO), ITALY
Telephone: +39-0125-53543
Web site: www.creabilistherapeutics.com
E-mail: sfumero@creabilistherapeutics.com
Contact: Silvano Fumero (CEO)
At a Glance
Status: SME
Date of foundation: 2003
Employees: 13
Main Activity
CREABILIS Therapeutics is a drug discovery and development biotech company, with the aim to discover, select, develop, and bring to commercial fruition novel and highly innovative therapeutic agents.
The main products of the company are:
- CT327 is a patented, PEGyated derivative of K-252a. CT327 is a selective inhibitor of TrkA intended for topical administration in psoriasis treatment. MoA: CT327 inhibits NGF signal responsible for keratinocyte hyperproliferation in psoriasis.
- CT335/6 are PEGylated derivatives of K-252a with shorter PEG chains intended to be developed as systemic treatment for Behçet's Disease. An application for orphan drug status is under submission. MoA: CT335/6 markedly decrease blood concentration of several pro-inflammatory cytokines, such as TNF-alpha, IFN-gamma, MIP-1 alpha, and so on.
- CT500s are HMGB1 BoxA variants generated to obtain higher resistance to plasma proteases and mantain same or increased activity. CT500s work as RAGE receptor antagonists, thus interfering with AGE (Advanced Glycation End-products) binding. CT500s are intended for the treatment of diabetes complications caused by excessive AGE accumulation in blood.
Company Strengths
LICENSE/TRADE-MARK/QUALITY CERTIFICATION/PATENT: Selected patents:
- An international patent application (PCT/EP 006/008374) has been filed on August 25th, 2006 by CREABILIS Therapeutics with the title: "Polymer conjugates of K-252a and derivatives thereof" which covers both composition-of-matter and use (systemic and topical) Claimed priorities: 25/08/2005; 27/09/2005; 07/06/2006
- "Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1" (Application No.: European Patent 04 425 665.9)
Customer References
Nautilus Biotech (Paris, France), Cephalon, Inc. (USA)
Sector
BIOTECHNOLOGY
MEDICAL BIOTECHNOLOGY
-Biofarmaceuticals
-Research & Development
-Other: Drug discovery
Type of Cooperation
GENERAL CO-OPERATION
-NEW PROJECTS DEVELOPMENT
-DEVELOPMENT OF NEW PRODUCTS
|
|
